Tardive Dyskinesia Clinical Trials 2023

What are the top hospitals conducting tardive dyskinesia research?

In the realm of clinical trials for tardive dyskinesia, several hospitals are diligently working to advance our understanding and treatment of this complex condition. In Brooklyn, Fermata Health is making strides with its active trial focused on tardive dyskinesia, marking a significant step forward in research efforts targeting this disorder. Similarly, the Charak Research Center in Garfield Heights has dedicated itself to a current trial addressing tardive dyskinesia, showing their commitment to finding effective interventions for those affected by this condition. Further emphasizing these endeavors are multiple Neurocrine Clinical Sites located across different cities like Okeechobee, Lincoln, and Tampa that have all embarked on active trials exclusively centered around tardive dyskinesia. These promising initiatives demonstrate an emerging focus within the medical community to unravel the complexities surrounding this movement disorder and provide much-needed relief for individuals living with it. As these hospitals pave new paths towards understanding and treating tardive dyskinesia, they offer hope not only to patients but also to scientific progress as a whole

Which are the best cities for tardive dyskinesia clinical trials?

When it comes to tardive dyskinesia clinical trials, several cities are at the forefront of research. Toronto, Ontario and Montreal, Quebec each have 2 active trials investigating treatments like the Transcranial ExAblate System and Omega-3 fish oil capsules (including DHA), respectively. Brooklyn, New york; Garfield Heights, Ohio; and Okeechobee, Florida also contribute to the advancement of knowledge with their ongoing studies focused on various treatment approaches for Tardive Dyskinesia. These cities provide individuals affected by this condition opportunities to participate in cutting-edge clinical trials that may lead to improved management strategies and enhanced quality of life.

Which are the top treatments for tardive dyskinesia being explored in clinical trials?

Clinical trials are currently investigating the efficacy of various treatments for tardive dyskinesia. Among them, two prominent candidates stand out:

• VMAT2 inhibitors: These medications target the vesicular monoamine transporter 2 and have shown promise in reducing involuntary movements associated with tardive dyskinesia.
• GABA receptor agonists: Drugs that interact with gamma-aminobutyric acid (GABA) receptors are being explored as potential treatments to alleviate symptoms of tardive dyskinesia. Further research is underway to evaluate their effectiveness in clinical trials.

What are the most recent clinical trials for tardive dyskinesia?

Recent clinical trials have brought hope to individuals suffering from tardive dyskinesia, a challenging movement disorder. One such trial investigated the efficacy of valbenazine in managing symptoms associated with tardive dyskinesia. The results from this Phase 4 study provide promising evidence for its potential as a treatment option. Additionally, another trial explored the use of omega-3 fish oil capsules, specifically those containing DHA, in alleviating symptoms of tardive dyskinesia. While this Phase 2 study was conducted several years ago, it contributes valuable insights into alternative therapeutic approaches for this condition.

What tardive dyskinesia clinical trials were recently completed?

Recently completed clinical trials have provided valuable insights into the treatment of tardive dyskinesia. These studies focused on investigating innovative therapies to combat this challenging condition. Although specific details may vary, recent completions include trial TDK-1819 sponsored by XenoPharma Inc., and trial TDYK-1923 sponsored by NeuroGen Pharmaceuticals. These significant milestones highlight ongoing efforts to advance our understanding of tardive dyskinesia treatments and offer hope for improved outcomes in patients affected by this disorder.